| EN

Orencia®:Abatacept injection

Orencia®:Abatacept injection


Moderate to severe active rheumatoid arthritis.


Abatacept may be used in combination with other DMARDs (other than TNF-α inhibitors), such as methotrexate, to treat moderate to severe active rheumatoid arthritis patients who do not respond favorably to other DMARDs.

It is the first innovative biologics developed by a PRC company jointly with a leading global pharmaceutical company that has been approved for sale in China, the first and only soluble CTLA4-Fc fusion protein approved for sale in China, and the first and only selective T-cell co-stimulation modulator in the autoimmune disease therapeutic area worldwide. Abatacept injection is an innovative biologic drug candidate for the treatment of moderate to severe rheumatoid arthritis, which has obtained the IDL in China in January 2020.

Abatacept injection distinguishes itself by the following core strengths:

● Superior Efficacy: Abatacept injection is clinically proven to effectively improve the condition of rheumatoid arthritis patients, decrease their disease activity and enhance their quality of life. Due to CTLA4-Fc’s mechanism of action, we believe that abatacept injection has the potential to expand its indications to other autoimmune diseases in the future;

● Proven safety profile;

●Better Patient Compliance: We believe subcutaneous administration improves patient convenience and persistence with treatment.